Topic: coronary artery disease
The first new option in 17 years, Biotronik’s sheathed emergency stent is used to seal off perforations in the blood vessels of the heart.
Verve Therapeutics is launching with $58.5 million access to CRISPR and base-editing tech and cardiologist and geneticist Sekar Kathiresan as CEO.
The drug-eluting balloon opens up the coronary arteries after they’ve reclogged without using a traditional drug coating.
2015 Fierce 15 company Shockwave Medical is going public, filing for a $75 million IPO on the Nasdaq with the ticker symbol SWAV.
The primary endpoint successes in patients with stable CAD or AMI set Idorsia up to plan the initiation of a phase 3 study.
XyloCor Therapeutics will move its lead asset, a gene therapy for chronic angina, into the clinic in 2019.
The FDA approved Biotronik’s stent to seal tears in coronary arteries, making it the first new treatment option in the indication in 17 years.
A discontinued heart disease drug will be developed for sickle cell, with Roche handing off its inclacumab antibody to Global Blood Therapeutics.
A tool called “polygenic risk scoring” could help physicians identify who faces a high risk of serious diseases.
Reva netted a CE mark for the first drug-eluting bioresorbable scaffold in lower-leg peripheral artery disease, and the company’s first in the space.